Drugmaker Novo Nordisk announced it is providing 340B covered entities 12-months-worth of refunds on four drug products including two of [...] …
Year: 2024
340B drugs have steadily increased as a share of U.S. branded outpatient pharmaceutical sales and reached 18% of the total [...] …
Hospitals in the 340B program should respond to increasing drugmaker contract pharmacy restrictions by opening their own pharmacies or selectively [...] …
Virginia Gov. Glenn Youngkin (R) late Friday vetoed a bill that would have prohibited drugmaker contract pharmacy restrictions on grantee [...] …
On the final day of Missouri’s legislative session, lawmakers overwhelmingly passed a bill to bar drugmaker 340B contract pharmacy restrictions [...] …
A Kansas law that prohibits drugmaker 340B contract pharmacy restrictions is set to take effect July 1, as result of [...] …
Maryland Gov. Wes Moore (D) this morning is signing legislation to make Maryland the sixth state to prohibit drugmaker 340B [...] …
CVS Health recently cited drug manufacturers’ contract pharmacy restrictions as one of the causes for a 19% year-over-year income decline [...] …
A federal judge scheduled an April 2025 trial date for AstraZeneca’s lawsuit against Arkansas’ 340B contract pharmacy access law as [...] …
The 340B program continued to expand in 2023, exceeding $124 billion in wholesale acquisition cost (WAC) sales—up from $107 billion [...] …